Early Methicillin-resistant Staphylococcus Aureus (MRSA) Therapy in Cystic Fibrosis (CF) (STAR-Too)

• ClinicalTrials.gov Identifier: NCT01349192
• Recruitment Status: Terminated
• First Posted: May 6, 2011
• Results First Posted: May 15, 2017
• Last Update Posted: May 15, 2017
• Sponsor: University of North Carolina, Chapel Hill
• Collaborators: CF Therapeutics Development Network Coordinating Center; Seattle Children's Hospital; Washington University School of Medicine; University of Washington; University of Colorado, Denver; Baylor College of Medicine; University of Alabama at Birmingham; Cook Children's Medical Center; University of Michigan; University of Florida; University of Texas Southwestern Medical Center; Children's Hospital Medical Center, Cincinnati; St. Louis Children's Hospital
• Information provided by (Responsible Party): Marianne Muhlebach, MD, University of North Carolina, Chapel Hill

Study Description

Brief Summary:

Purpose: There has been a recent, rapid increase in prevalence of Methicillin-resistant Staphylococcus aureus (MRSA) among patients with Cystic Fibrosis (22% across US CF centers in 2009). Some epidemiologic studies suggest possible worse outcomes, a recent analyses showing this with chronic but not intermittent MRSA. Given the chronic difficult to treat lung infections in CF it is unclear how the onset of MRSA should be approached. This randomized, controlled, interventional study seeks to determine if an early eradication protocol is effective for eradication of MRSA and will provide an opportunity to obtain data regarding early clinical impact of new isolation of MRSA.

Participants: Cystic fibrosis patients with new isolation of MRSA from their respiratory culture on a routine clinic visit.

Procedures (methods): Randomized, open-label, multi-center study comparing use of an eradication protocol to an observational group who receives the current standard of care i.e. treatment for MRSA only with pulmonary exacerbations.

Condition or disease	Intervention/treatment	Phase
Cystic Fibrosis; Methicillin-resistant Staphylococcus Aureus	Drug: Rifampin; Drug: Trimethoprim/Sulfamethoxazole; Drug: Minocycline; Drug: Mupirocin; Drug: chlorhexidine gluconate oral rinse; Drug: 2% Chlorhexidine solution wipes; Behavioral: Environmental Decontamination	Phase 2

Detailed Description:

The STAR-too study is a randomized, open label, multi-center study in CF patients with new MRSA isolated from the respiratory tract (sputum or oropharyngeal (OP) swab). The purpose of the study is to compare use of a two week eradication treatment protocol to an observational group treated for MRSA only when respiratory symptoms meet the criteria for a protocol defined pulmonary exacerbation during the first 28 days of the study. A total of 90 participants, four years of age or older, with new MRSA infection are planned to be randomized in a 1:1 fashion to either the treatment arm or to the observational control arm. Randomization is stratified by age, P. aeruginosa status at screening and site. Each participant randomized to the treatment arm receives two oral antibiotics for 14 days, topical antibacterial treatment of skin and nares, and a three week environmental decontamination for high risk areas and equipment. Each participant randomized to the observational control arm is followed clinically with usual care except to treat new or worsening pulmonary symptoms with antibiotics between screening and Day 28 only when participant meets criteria for a protocol defined exacerbation. Participants continue in the study for 6 months with study visits at Day 84 and Day 168 corresponding with their normal quarterly visits, this extension of observation provides additional data regarding natural history of MRSA infection and durability of the eradication protocol. The primary outcome is the proportion of participants with MRSA eradicated from respiratory tract cultures at Day 28. The secondary outcomes number of, and time to, pulmonary exacerbations, and use of antibiotics.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 47 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Single (Investigator)
• Masking Description: Although this is an open-label study, the PIs and operational study team will remain blinded to the study arm assignments of the aggregate study population and will not view aggregate study results by study arm until after database lock.
• Primary Purpose: Treatment
• Official Title: Early MRSA Therapy in CF - Culture Based vs. Observant Therapy (Treat or Observe) (Star-TOO - STaph Aureus Resistance - Treat or Observe)
• Actual Study Start Date: April 2011
• Actual Primary Completion Date: January 2015
• Actual Study Completion Date: May 2015

Arms and Interventions

Arm	Intervention/treatment
Experimental: Treatment; Subjects are treated with two oral antibiotics, topical antibiotics, and are instructed to use environmental decontamination techniques.	Drug: Rifampin; Adult Dose: 300mg twice daily for 14 days. Pediatric Dose: <40kg : 15mg/kg daily for 14 days divided every 12 hours.; Other Name: Rifadin, Rimactane; Drug: Trimethoprim/Sulfamethoxazole; Adult Dose: 320/1600 orally twice daily for 14 days. Pediatric Dose: <40 kg : 8mg/kg trimethoprim / 40 mg/kg sulfamethoxazole twice a day for 14 days.; Other Name: Bactrim, Septra; Drug: Minocycline; only subjects greater or equal to 8 years of age, who are not able to tolerate TMP/SMX or whose screening MRSA is resistant to TMP/SMX should be prescribed minocycline. Adult dose: 100 mg orally twice daily for 14 days Pediatric dose: < 50 kg : 2mg/kg orally twice daily for 14 days not to exceed 200mg per day.; Other Name: Cleeravue-M, Dynacin, Minocin, Myrac, Solodyn, Vectrin; Drug: Mupirocin; 1 gram 2% nasal ointment generously applied to each nostril using a cotton swab twice daily for 14 days.; Other Name: Bactroban, Centany; Drug: chlorhexidine gluconate oral rinse; for subjects able to swish without swallowing. 0.12% chlorhexidine gluconate oral rinse twice daily for 14 days.; Drug: 2% Chlorhexidine solution wipes; whole body wash solution wipes once daily for first 5 days.; Behavioral: Environmental Decontamination; wipe down high touch surfaces and medical equipment with surface disinfecting wipes daily for the first 21 days. wash all linens and towels in hot water once weekly for three weeks.; Other Name: Sani-Cloth Plus
No Intervention: Observational; Subjects are tracked and not treated for their MRSA. If the subject reaches a protocol defined exacerbation within the first 28 days then they will be treated per choice of their primary Pulmonologist.

Outcome Measures

Primary Outcome Measures :

1. MRSA Culture Status [ Time Frame: Day 28 ]
   Proportion of subjects with a negative culture for MRSA at Day 28.

Secondary Outcome Measures :

1. Antibiotic Use (Proportion of Subjects) [ Time Frame: 6 months ]
   Proportion of subjects treated with oral, inhaled, and IV antibiotics over the 6 month study.
2. Antibiotic Use (Days of Use Per Subject) [ Time Frame: 6 months ]
   Days of use of oral, inhaled, and IV antibiotics over the 6 month study.
3. Pulmonary Exacerbations [ Time Frame: 28 days ]
   Proportion of subjects with a protocol-defined pulmonary exacerbation (PE) between baseline and day 28 who are treated with antibiotics active against MRSA.

Eligibility Criteria

• Ages Eligible for Study: 4 Years to 45 Years (Child, Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Male or female ≥ 4 and ≤ 45 years of age at the Screening Visit.

2. Documentation of a CF diagnosis as evidenced by one or more clinical features consistent with the CF phenotype and one or more of the following criteria:

   • sweat chloride ≥ 60 mEq/liter by quantitative pilocarpine iontophoresis test (QPIT)
   • two well-characterized mutations in the cystic fibrosis transmembrane conductive regulator (CFTR) gene
   • Abnormal nasal potential difference (change in NPD in response to a low chloride solution and isoproteronol of less than -5 mV)

3. First OR early repeat MRSA colonization defined as:

   • First MRSA colonization: first documented isolation of MRSA from respiratory tract occurred ≤ 6 months prior to screening
   • OR Early repeat MRSA colonization:

   MRSA was previously isolated from the respiratory tract (≤ 2 times), but this was followed by at least 1 year of documented negative cultures for MRSA as noted below:

   -- At least 2 cultures performed at least 3 months apart to document 1 year of culture negativity. Each of these cultures should be documented to have been collected at least 1 week after end of any antibiotic prescription with MRSA activity.

   Patient again recently positive for MRSA from the respiratory tract (within 6 months prior to screening)

4. Clinically stable with no significant changes in health status within the 14 days prior to screening
5. Written informed consent (and assent when applicable) obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study

A repeat culture from the respiratory tract is obtained at screening but does not have to be positive to be able to enter the study.

Exclusion Criteria:

1. Received antibiotics with activity against MRSA within 28 days prior to screening (see study manual for list of antibiotics)
2. Use of an investigational agent within 28 days prior to screening
3. For subjects ≥ 6 years of age: FEV1 at screening < 30% of predicted for age based on the Wang (males < 18 years, females < 16 years) or Hankinson (males ≥ 18 years, females ≥ 16 years) standardized equations
4. MRSA from the screening culture resistant to rifampin OR resistant to both TMP/SMX and minocycline
5. History of intolerance to oral rifampin, or topical chlorhexidine or mupirocin
6. History of intolerance to both TMP/SMX and minocycline
7. < 8 years of age and either allergic or intolerant to TMP/SMX or screening MRSA resistant to TMP/SMX
8. ≥ 8 years of age and allergic or intolerant to TMP/SMX and screening MRSA resistant to minocycline
9. ≥ 8 years of age and allergic or intolerant to minocycline and screening MRSA resistant to TMP/SMX
10. For females of child bearing potential: pregnant, breastfeeding, or unwilling to use barrier contraception through Day 15 of the study
11. Abnormal renal function at Screening, defined as estimated creatinine clearance <50 mL/min using the Cockcroft-Gault equation
12. Abnormal liver function at the time of screening, defined as ≥2x upper limit of normal (ULN), of serum aspartate transaminase (AST) or serum alanine transaminase (ALT)
13. History of solid organ or hematological transplantation
14. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.

Contacts and Locations

Locations

United States, Alabama

The Children's Hospital-University of Birmingham

Birmingham, Alabama, United States, 35233

United States, Colorado

The Children's Hospital

Aurora, Colorado, United States, 80045

United States, Florida

University of Florida

Gainesville, Florida, United States, 32611

United States, Michigan

University of Michigan Health System

Ann Arbor, Michigan, United States, 48109-5212

United States, Minnesota

Children's Hospitals and Clinics of Minnesota Minneapolis

Minneapolis, Minnesota, United States, 55404

United States, Missouri

St. Louis Children's Hospital

St. Louis, Missouri, United States, 63110

United States, North Carolina

N.C Memorial Hospital and N.C Children's Hospital

Chapel Hill, North Carolina, United States, 27599

United States, Ohio

CFF Care Center & Pediatric Program Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio, United States, 45229-3026

United States, Texas

University of Texas Southwestern Medical Center

Dallas, Texas, United States, 75390

Cook Children's Medical Center

Fort Worth, Texas, United States, 76104

Baylor College of Medicine

Houston, Texas, United States, 77030

United States, Washington

Seattle Children's

Seattle, Washington, United States, 98145-9807

University of Washington Medical Center

Seattle, Washington, United States, 98195

Sponsors and Collaborators

University of North Carolina, Chapel Hill

CF Therapeutics Development Network Coordinating Center

Seattle Children's Hospital

Washington University School of Medicine

University of Washington

University of Colorado, Denver

Baylor College of Medicine

University of Alabama at Birmingham

Cook Children's Medical Center

University of Michigan

University of Florida

University of Texas Southwestern Medical Center

Children's Hospital Medical Center, Cincinnati

St. Louis Children's Hospital

Investigators

• Principal Investigator: Marianne S Muhlebach, MD; UNC Children's Hospital
• Principal Investigator: Chris Goss, MD; University of Washington

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Muhlebach MS, Beckett V, Popowitch E, Miller MB, Baines A, Mayer-Hamblett N, Zemanick ET, Hoover WC, VanDalfsen JM, Campbell P, Goss CH; STAR-too study team. Microbiological efficacy of early MRSA treatment in cystic fibrosis in a randomised controlled trial. Thorax. 2017 Apr;72(4):318-326. doi: 10.1136/thoraxjnl-2016-208949. Epub 2016 Nov 15.

• Responsible Party: Marianne Muhlebach, MD, Professor, Pediatric Pulmonolgy, University of North Carolina, Chapel Hill
• ClinicalTrials.gov Identifier: NCT01349192
• Other Study ID Numbers: STAR-too-10K0
• First Posted: May 6, 2011
• Results First Posted: May 15, 2017
• Last Update Posted: May 15, 2017
• Last Verified: April 2017

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

Keywords provided by Marianne Muhlebach, MD, University of North Carolina, Chapel Hill:

MRSA; Cystic Fibrosis; Early Infection; Treatment

Additional relevant MeSH terms:

Staphylococcal Infections; Cystic Fibrosis; Fibrosis; Pathologic Processes; Pancreatic Diseases; Digestive System Diseases; Lung Diseases; Respiratory Tract Diseases; Genetic Diseases, Inborn; Infant, Newborn, Diseases; Gram-Positive Bacterial Infections; Bacterial Infections; Bacterial Infections and Mycoses; Infections; Chlorhexidine; Chlorhexidine gluconate; Minocycline; Rifampin; Trimethoprim; Sulfamethoxazole; Mupirocin; Anti-Infective Agents, Local; Anti-Infective Agents; Disinfectants; Dermatologic Agents; Anti-Bacterial Agents; Antibiotics, Antitubercular; Antitubercular Agents; Leprostatic Agents; Nucleic Acid Synthesis Inhibitors